RegenxBio rally fades fast after biotech reports setbacks, hospitalization in gene therapy study

RegenxBio $RGNX has some explaining to do today.

In its quarterly report the gene therapy company reported that it experienced several setbacks during its Phase I/II study of RGX-501, one of 4 pipeline programs at the biotech that’s being developed for homozygous familial hypercholesterolemia (HoFH) in a trial underway at the University of Pennsylvania.